ArticleArchiv der Pharmazie2026
From Identification to Enzymatic Activity Profiling: Comprehensive Characterization of BloCAβ, a Probiotic β-Carbonic Anhydrase From Bifidobacterium longum.
Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The microbiota comprises communities of microorganisms that establish complex relationships with the host and play key roles in physiology, metabolism, and immunity. Increasing evidence highlights microbiota alterations in several diseases, particularly those driven by oxidative stress-induced inflammation. Thus, identifying probiotic enzymes implicated in essential metabolic pathways is highly relevant to the development of future strategies targeting dysbiosis and related diseases. Herein, we report the first biochemical characterization of β-class carbonic anhydrase (CA) from Bifidobacterium longum (BloCAβ) by inhibition and activation profiles. The enzyme was recombinantly expressed, purified, and kinetically characterized, displaying a catalytic efficiency within the same order of magnitude as, although lower than, that of human (h)CA I. The functional profile of this novel CA was explored using a panel of commercial sulfonamides, sulfamides, sulfamates, and inorganic/organic anions as inhibitors. Furthermore, several biogenic amines and amino acids were assessed as potential activators of BloCAβ, and their activation profiles were compared with those of hCAs I and II. The cellular effects of selected BloCAβ activators was further evaluated in human macrophages under basal and proinflammatory conditions, while the safety profile was assessed in human intestinal epithelial cells (HIECs). Among them, serotonin (38) was found to significantly enhance cell metabolic activity in both conditions and preserve the metabolic activity of HIECs, further supporting its biocompatibility. Overall, these results provide the first biochemical and functional characterization of BloCAβ and establish a biochemical basis for future studies investigating the physiological role of probiotic CAs in bacterial models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.